Clipboard Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare per-diem staffing marketplace with 90%+ shift-fill rate and $100M revenue; profitable since 2022 backed by Sequoia competing with Shiftkey and CareRev for nurse per-diem placement.
About
Clipboard Health is a healthcare staffing marketplace that connects per-diem nurses, CNAs, and allied health professionals with healthcare facilities (nursing homes, hospitals, urgent care centers) for shift work — achieving a 90%+ shift-fill reliability rate versus the 60% industry average for traditional staffing agencies, and maintaining profitability since 2022. A Y Combinator graduate, Clipboard Health reached $100 million in annual revenue within three years of founding, raised $94.1 million total led by Sequoia Capital, and serves tens of thousands of healthcare professionals across 1,000+ facilities.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.